Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Last spring, my colleague received an intriguing email from Mark Cuban. From there, a story was born. Read on for more.
The need-to-know this morning
- Roivant and its subsidiary Priovant announced positive results across two Phase 3 studies of their drug Lisraya in non-infectious uveitis, an inflammatory eye disease that can lead to vision loss. Lisraya was recently approved to treat dermatomyositis, another inflammatory condition. Roivant said it will seek an expanded FDA approval for Lisraya in the first half of 2027.
Cuban’s Cost Plus Drugs is getting into rare disease
Mark Cuban’s Cost Plus Drugs, the online pharmacy that aims to lower drug costs by bypassing middlemen, has mostly been selling generic drugs. But the company is getting into a much more complicated field — experimental rare disease therapies.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
